Venous Insufficiency

7
Pipeline Programs
2
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
4
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
7 programs
2
4
1
Antistax film coated tabletsPhase 41 trial
Antistax®Phase 31 trial
BNS003Phase 31 trial
Read vine leaf extractPhase 31 trial
Red vine leaf extractPhase 31 trial
+2 more programs
Active Trials
NCT02191163Completed71
NCT02191280Completed260
NCT02191254Completed245
+4 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Boehringer IngelheimAntistax film coated tablets
Boehringer IngelheimRed vine leaf extract
Boehringer IngelheimRead vine leaf extract
Boehringer IngelheimBNS003
Boehringer IngelheimAntistax®
Boehringer IngelheimAntistax®
Boehringer IngelheimAntistax®, low dose

Clinical Trials (7)

Total enrollment: 1,273 patients across 7 trials

NCT02184234Boehringer IngelheimAntistax film coated tablets

Tolerability of Antistax® in Patients Suffering From Chronic Venous Insufficiency (CVI)

Start: Jun 200165 patients
Phase 4Completed
NCT00855179Boehringer IngelheimRed vine leaf extract

Assess the Efficacy and Tolerability of Antistax Film-coated Tablets in Patients With Chronic Venous Insufficiency

Start: Mar 2009250 patients
Phase 3Completed
NCT00292435Boehringer IngelheimRead vine leaf extract

Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)

Start: Mar 2006202 patients
Phase 3Completed
NCT02211898Boehringer IngelheimBNS003

Clinical Study of BNS003 on Swelling in Legs Due to Venous Reflux

Start: Jul 2004180 patients
Phase 3Completed
NCT02191254Boehringer IngelheimAntistax®

Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency

Start: Apr 2004245 patients
Phase 3Completed
NCT02191163Boehringer IngelheimAntistax®

Efficacy of Antistax® in Improving Microcirculation of the Skin in the Leg in Patients Suffering From Chronic Venous Insufficiency

Start: Apr 200271 patients
Phase 2Completed
NCT02191280Boehringer IngelheimAntistax®, low dose

Antistax® in Patients With Chronic Venous Insufficiency

Start: Apr 1998260 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space